
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Paris - Magadelene A. Dohill, M.D. examined pediatric patients and atopic dermatitis at the World Congress of Dermatology, focusing on a rather unique question: Why use peanut oil as a vehicle when so many atopics suffer from peanut allergies?